Already a Bloomberg.com user?
Sign in with the same account.
NEW YORK (AP) — A U.K. court has ruled in favor of Teva Pharmaceutical in regard to dispute over a patent supporting its multiple sclerosis drug.
The United Kingdom High Court of Justice ruled that a patent on Copaxone is valid and refused to declare that a proposed generic version made by Mylan Inc. would not infringe on that patent, the company said Wednesday. The patent expires May 23, 2015.
A U.S. court made a similar ruling in late June, finding that several patents on Copaxone were valid. The last of the patents expires in 2015, and other companies like Mylan cannot sell their own versions of the drug until then.
Copaxone is the biggest-selling multiple sclerosis drug in the world, and it is also the best seller among Teva's branded drugs. The company expects $3.8 billion in worldwide sales of Copaxone in 2012. Teva is also the world's largest maker of low-cost generic drugs.
Shares of Teva Pharmaceutical Industries Ltd. were unchanged at $39.29 in morning trading. Mylan shares rose 12 cents to $21.71.